Acumen Pharmaceuticals Inc

ABOS

Company Profile

  • Business description

    Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

  • Contact

    1210-1220 Washington Street
    Suite 210
    NewtonMA02465
    USA

    T: +1 617 344-4190

    https://www.acumenpharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    61

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.2056.10-0.62%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,241.48266.69-1.13%
NASDAQ24,328.38181.38-0.74%
Nikkei 22559,175.06314.630.53%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,829.9053.30-0.60%
SSE Composite Index3,570.2114.37-0.40%

Market Movers